Hims & Hers Health, Inc. (HIMS) Q2 Earnings and Revenues Beat Estimates
Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to loss of $0.03 per share a year ago.
Shares of Hims & Hers, known for hair-loss treatments and Viagra, rally amid market panic
Shoppers might be spending less or seeking cheaper deals on takeout food and household items, and investors on Monday were panicking about the U.S. economy. But Hims & Hers Health Inc. — the online telehealth platform best known for selling hair-loss treatments, Viagra and Cialis — said customers are still piling in.
Hims & Hers (HIMS) Gains 45.8% in Three Months: What's Next?
Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Got $200? 2 Best Growth Stocks to Buy and Hold Forever
Spending on healthcare and online purchases is rising even as consumer wallets remain constrained. Hims & Hers offers virtual care services and prescriptions through a simple recurring subscription plan.
Hims & Hers Health Stock Flashing Buy Signal Before Earnings
After a late-May bull gap on the charts, healthcare stock Hims & Hers Health Inc (NYSE:HIMS) steadily worked higher to snag a record high of $25.74 on June 18.
Should You Buy Hims & Hers (HIMS) Stock Ahead of Q2 Earnings?
Continued solid uptake of Hims & Hers (HIMS) offerings and expanding subscriber base are likely to have driven its performance in the second quarter.
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?
Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Hims & Hers Health (HIMS) Run Higher on Rising Earnings Estimates?
Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Game-Changing Stocks on the Edge of Unprecedented Gains
Uncovering the best game-changing stocks to buy is a true holy grail for achieving considerable financial returns while investing. Here are three standout companies ready to shift the valuation landscape.
Red-Hot Prescription Stock Flashing A Bullish Signal
Prescription stock Hims & Hers Health (HIMS) is down 2.8% to trade at $22.45 today, and last week suffered a 10.6% drawdown. The upside is that the pullback has HIMS brushing up against a historically bullish trendline, if past is precedent.
Is Hims & Hers Health (HIMS) Stock Outpacing Its Medical Peers This Year?
Here is how Hims & Hers Health, Inc. (HIMS) and TransMedics (TMDX) have performed compared to their sector so far this year.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
